title: Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study.
abstract: Neurocysticercosis is a common cause of acquired seizure disorder in developing countries, including India. The role of antiparasitic (albendazole) therapy for seizure control and resolution of lesions is still controversial due to a lack of adequately controlled studies. The objective of the present study was to evaluate the role of albendazole therapy for neurocysticercosis patients with two or more lesions to achieve seizure-free status and resolution of lesions. This was a randomised controlled study in which patients suffering from neurocysticercosis were prospectively followed up for more than 5 years (from January 1997 to January 2005). Patients were divided into two groups: patients in group A (n=150) were treated with a combination of tapered doses of dexamethasone and albendazole, plus antiepileptic drugs; patients in group B (n=150) were treated with antiepileptic drugs plus a placebo control. Patients were followed up every month for the first 6 months and then at 3-month intervals thereafter up to 5 years. Variables of interest were (i) recurrence of seizures; (ii) encephalopathy (headache/vomiting/altered sensorium); (iii) need for subsequent hospital admission; (iv) death; (v) resolution of lesions on follow-up CT. During the first 6 months and at intervals thereafter, increased seizure frequency and hospital readmissions, and increased incidence of encephalopathy were observed in group A (p=0.01), and two patients in this group died with intractable seizures and encephalopathy. A greater proportion of lesions completely resolved in group B (p=0.05), whereas a greater proportion of lesions calcified in group A (p=0.05). Albendazole plus antiepileptic drugs did not have greater beneficial effects than antiepileptic drugs alone, but may have an adverse effect with respect to seizure control, encephalopathy, recurrent hospital admissions, calcification of lesions and cost of treatment.
authors.affiliation: Department of Neurology, Burdwan Medical College Hospital, West Bengal 713 103, India. drkamaleshdas@rediffmail.com
authors.forename: Kamalesh
authors.initials: K
authors.lastname: Das
authors.forename: Gouranga Prasad
authors.initials: GP
authors.lastname: Mondal
authors.forename: Mousumi
authors.initials: M
authors.lastname: Banerjee
authors.forename: Bansi Badan
authors.initials: BB
authors.lastname: Mukherjee
authors.forename: Om Prakash
authors.initials: OP
authors.lastname: Singh
mesh_terms: D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000871:Anthelmintics / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D001921:Brain / Q000469:parasitology / Q000473:pathology / Q000503:physiopathology; D004569:Electroencephalography; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D020019:Neurocysticercosis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D012640:Seizures / Q000209:etiology*; D014057:Tomography, X-Ray Computed
chemical_list: D000871:Anthelmintics; D000977:Antiparasitic Agents; D015766:Albendazole